The company is updating its financial guidance for 2021/22 to reflect the
- “We are off to a good start to the year with 6% organic growth in Q1. Despite the challenges created by the pandemic, we continue to grow across all our business areas and sales regions, which means that we continue to help more and more people with intimate healthcare needs live better lives. In Q1, we have yet again managed to keep our people safe, while continuing to serve our customers. This makes me very proud,” says
Coloplast CEOKristian Villumsen .
In Q1,
- “Our Chronic Care business delivered a satisfactory first quarter driven by solid growth in
Europe due to a normalised growth in new patients as well as continued strong performance in many of our Emerging markets.China remains impacted by COVID-19 and weaker consumer sentiment, and as expected the US posted a slow start to the year impacted by a high baseline in Q1 last year and continued lower growth in new patients in Continence Care due to COVID-19,” saysKristian Villumsen . - “Growth in the Interventional Urology business was impacted by a high baseline in Men’s Health, but the underlying growth was solid in the Men’s and Women’s Health businesses in the US as well as the Endourology business in
Europe . Our Wound &Skin Care business delivered a very strong quarter, with Wound Care delivering 17% organic growth, driven by solid momentum inEurope and the Biatain® Silicone portfolio,” saysKristian Villumsen .
Acquisition of
On
The transaction is targeted to close on
With the acquisition,
2021/22 financial guidance updated to reflect the acquisition of
Organic revenue growth guidance is unchanged, expected around 7% at constant exchange rates. Reported growth in DKK excluding
The reported EBIT margin before special items is expected around 31% from previously around 32%, due to around
Capital expenditures expected to be around
CONTACTS
Senior Director, Corporate Communications
+45 49 11 26 08
dkdk@coloplast.com
Ellen Bjurgert
Vice President, Investor Relations
+45 49 11 33 76
dkebj@coloplast.com
Financial highlights and key ratios
DKKm | 2021/22 – Q1 | 2020/21 – Q1 | Change |
Revenue | 5,169 | 4,738 | 9% |
EBIT before special items | 1,649 | 1,536 | 7% |
EBIT margin before special items | 32% | 32% | |
Special items | -34 | - | |
EBIT after special items | 1,615 | 1,536 | 5% |
EBIT margin after special items | 31% | 32% | |
Net profit for the period | 1,207 | 1,136 | 6% |
Sales performance by business area
DKKm | 2021/22 - Q1 | 2020/21 - Q1 | Organic growth | Reported growth |
Ostomy Care | 2,098 | 1,932 | 6% | 9% |
Continence Care | 1,844 | 1,705 | 5% | 8% |
Interventional Urology | 579 | 536 | 5% | 8% |
Wound & | 648 | 565 | 12% | 15% |
Net revenue | 5,169 | 4,738 | 6% | 9% |
Sales performance by region
DKKm | 2021/22 – Q1 | 2020/21 – Q1 | Organic growth | Reported growth |
European markets | 2,959 | 2,737 | 6% | 8% |
Other developed markets | 1,285 | 1,174 | 5% | 9% |
Emerging Markets | 925 | 827 | 8% | 12% |
Net revenue | 5,169 | 4,738 | 6% | 9% |
Attachment
- 2021_2022_Q1_PM_ENG_25_1_FINAL
© OMX, source